$45 million; and,Total stock-based compensation recognized in 2011 will be in the range of $15 million to $20 million.
Auxilium will focus on the following strategic priorities in 2011: Maximize XIAFLEX net revenues for Dupuytren's contracture in the U.S. and global Testim revenues;Support Pfizer in the launch of Xiapex for Dupuytren's contracture in the EU;Complete enrollment in the Peyronie's disease phase III double-blind studies in the first quarter of 2011, with top-line results anticipated in first half of 2012; and,Advance XIAFLEX new indication(s).
Fourth Quarter 2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the quarter ended December 31, 2010: Quarter EndQuarter EndIncrease12/31/201012/31/2009 (Decrease)Testim U.S. Revenue
$52.1$42.223%Testim Ex – U.S. & Contract Revenue
1.34.9(74%)Total Testim Revenue
$53.4$47.113%XIAFLEX U.S. Revenue
$7.3-n/aXIAFLEX Contract Revenue
1.10.922%Total XIAFLEX Revenue
$8.4$0.9845%Total Worldwide Revenue
$61.8$48.029%Contract Revenues represent amortization of previously received upfront and milestone payments.
Fourth Quarter 2010 Financial Detail The net loss for the fourth quarter of 2010 was $(16.4) million, or $(0.34) per share, compared to a net loss of $(11.9) million, or $(0.25) per share, reported for the fourth quarter of 2009. Net loss for the fourth quarter of 2010 includes total stock-based compensation expense of $6.0 million, compared to $4.4 million for the fourth quarter of 2009.
Gross margin on net revenues was 72% for the quarter ended December 31, 2010 compared to 78% for the comparable period in 2009. Gross margin reflects the costs of products sold, royalty obligations due to the Company's licensors, the amortization of the deferred costs associated with the Pfizer con
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 20112
. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT3
. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC4
. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board5
. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team6
. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference7
. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group8
. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial9
. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results10
. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.11
. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing